To view the full citation, click here.
Integration of Biomonitoring Exposure Data Into the Risk Assessment Process
Risk Policy Report, 2004
Open access, peer-reviewed publications ensure that knowledge is a public good. HESI believes that accessible research is critical for equitable engagement, diverse collaboration, and increased interdisciplinary conversation. We strive to achieve open access on all publications, and more than 200 publications from HESI programs have been published in the last decade.
Risk Policy Report, 2004
To view the full citation, click here.
Environmental Health Perspectives, 2006
The probability of nonoccupational exposure to phthalates is high given their use in a vast range of consumables, including personal care products (e.g., perfumes, lotions, cosmetics), paints, industrial plastics, and certain medical devices and pharmaceuticals.
Frontiers in Toxicology, 2022
This case study demonstrates the utility of combining the TGx-DDI biomarker and CometChip® to resolve conflicting genotoxicity data and provides further ...
Regulatory Toxicology and Pharmacology, 2013
Cardiovascular (CV) safety concerns are a significant source of drug development attrition in the pharmaceutical industry today.
Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2013
Inhibin B is a heterodimer glycoprotein that downregulates follicle-stimulating hormone and is produced predominantly by Sertoli cells.
Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2013
Inhibin B was measured in plasma samples obtained from 34 healthy male subjects selected on criteria typical for a phase I clinical trial across a wide age range (19–70 years).
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.